Screening for BRCA1 and BRCA2 mutations in Eastern Finnish breast/ ovarian cancer families

Clinical Genetics

Volumn 72, Issue 4, 2007, Pages 311-320

  Hartikainen, Jaana ^a,b   Kataja, V ^b   Pirskanen, M ^c   Arffman, A ^d   Ristonmaa, U ^b   Vahteristo, P ^e   Ryynanen M ^f   Heinonen, S ^b   Kosma, V M ^a,b   Mannermaa, A ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c Oy Jurilab Ltd   (Finland)

^d NOKIA RESEARCH CENTER   (United States)

^e UNIVERSITY OF HELSINKI   (Finland)

^f OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

BRCA1; BRCA2; Breast cancer; Familial; Germline; Mutation; Ovarian cancer

Indexed keywords

ADENINE; BRCA1 PROTEIN; BRCA2 PROTEIN; CYTOSINE; GUANINE; THYMINE;

5' UNTRANSLATED REGION; ALLELE; ARTICLE; BREAST CANCER; CANCER SCREENING; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; EXON; FEMALE; FINLAND; FREQUENCY ANALYSIS; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; GEOGRAPHIC DISTRIBUTION; HAPLOTYPE; HETERODUPLEX ANALYSIS; HUMAN; INTRON; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; OVARY CANCER; PREVALENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

BREAST NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; FINLAND; GENES, BRCA1; GENES, BRCA2; GENOTYPE; HAPLOTYPES; HUMANS; MASS SCREENING; MICROSATELLITE REPEATS; MUTATION; OVARIAN NEOPLASMS; POLYMORPHISM, GENETIC; PREVALENCE;

EID: 34548555723     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2007.00866.x     Document Type: Article

References (40)

1. Claus EB, Schildtkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer 1996: 77: 2318-2324.
2. Finnish Cancer Registry. Cancer statistics. Retrieved March 20, 2007, from http://www.cancerregistry.fi
3. Miki Y, Swensen J, Shattuck-Eidens D et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994: 266: 66-71.
4. Wooster R, Bignell G, Lancaster J et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995: 378: 789-792.
5. Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer 2000: 83: 1301-1308.
6. Ford D, Easton DF, Stratton M et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998: 62: 676-689.
7. Antoniou A, Pharoah PDP, Narod S et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected case series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet 2003: 72: 1117-1130.
8. Gayther SA, Mangion J, Russell P et al. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet 1997: 15: 103-105.
9. Thompson D, Easton D. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 2001: 68: 410-419.
10. Vehmanen P, Friedman LS, Eerola H et al. Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: Evidence for additional susceptibility genes. Hum Mol Genet 1997: 6: 2309-2315.
11. Vehmanen P, Friedman LS, Eerola H et al. A low proportion of BRCA2 mutations in Finnish breast cancer families. Am J Hum Genet 1997: 60: 1050-1058.
12. Roth S, Kristo P, Auranen A et al. A missense mutation in the BRCA2 gene in three siblings with ovarian cancer. Br J Cancer 1998: 77: 1199-1202.
13. Huusko P, Pääkkönen K, Launonen V et al. Evidence of founder mutations in Finnish BRCA1 and BRCA2 families. Am J Hum Genet 1998: 62: 1544-1548.
14. Sarantaus L, Huusko P, Eerola H et al. Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland. Eur J Hum Genet 2000: 8: 757-763.
15. Syrjäkoski K, Vahteristo P, Eerola H et al. Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst 2000: 92: 1529-1531.
16. Sarantaus L, Auranen A, Nevanlinna H. BRCA1 and BRCA2 mutations among Finnish ovarian carcinoma families. Int J Oncol 2001: 18: 831-835.
17. Sarantaus L, Vahteristo P, Bloom E et al. BRCA1 and BRCA2 mutations among 233 unselected Finnish ovarian carcinoma patients. Eur J Hum Genet 2001: 9: 424-430.
18. Pääkkönen K, Sauramo S, Sarantaus L et al. Involvement of BRCA1 and BRCA2 in breast cancer in a Western Finnish sub-population. Genet Epidemiol 2001: 20: 239-346.
19. Eerola H, Vahteristo P, Sarantaus L et al. Survival of breast cancer patients in BRCA1, BRCA2, and non-BRCA1/2 breast cancer families: A relative survival analysis from Finland. Int J Cancer 2001: 93: 368-372.
20. Vahteristo P, Eerola H, Tamminen A, Blomqvist C, Nevanlinna H. A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families. Br J Cancer 2001: 84: 704-708.
21. Syrjäkoski K, Kuukasjärvi T, Waltering K et al. BRCA2 mutations in 154 Finnish male breast cancer patients. Neoplasia 2004: 6: 541-545.
22. Norio R, Nevanlinna HR, Perheentupa J. Hereditary diseases in Finland; rare flora in rare soul. Ann Clin Res 1973: 5: 109-141.
23. Nyström-Lahti M, Sistonen P, Mecklin JP et al. Close linkage to chromosome 3p and conservation of ancestral founding haplotype in hereditary nonpolyposis colorectal cancer families. Proc Natl Acad Sci U S A 1994: 91: 6054-6058.
24. Moisio A, Sistonen P, Weissenbach J, de la Chapelle A, Peltomäki P. Age and origin of two common MHL1 mutations predisposing to hereditary colon cancer. Am J Hum Genet 1996: 59: 1243-1251.
25. MännistöS, Pietinen P, Pyy M, Palmgren J, Eskelinen M, Uusitupa M. Body-size indicators and risk of breast cancer according to menopause and estrogen-receptor status. Int J Cancer 1996: 68: 8-13.
26. Vandenplas S, Grobler-Rabie A, Brebner K et al. Blot hybridization of genomic DNA. J Med Genet 1984: 21: 164-172.
27. Plummer SJ, Anton-Culver H, Webster L et al. Detection of BRCA1 mutations by the protein truncation test. Hum Mol Genet 1995: 10: 1989-1991.
28. Tavtigian SV, Simard J, Rommens J et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 1996: 12: 333-337.
29. Friedman LS, Ostermeyer EA, Szabo CI et al. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat Genet 1994: 8: 399-404.
30. Friedman LS, Gayther SA, Kurosaki T et al. Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet 1997: 60: 313-319.
31. Couch FJ, Farid LM, DeShano ML et al. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet 1996: 13: 123-125.
32. Hartikainen J, Kataja V, Mannermaa A. A novel BRCA2 gene mutation, 4081 insA, in a Finnish breast/ovarian cancer family associated with favourable clinical course [abstract]. Breast Cancer Res 2000: 2 (Suppl 1): P1.03.
33. Barkardottir RB, Sarantaus L, Arason A et al. Haplotype analysis in Icelandic and Finnish BRCA2 999del5 breast cancer families. Eur J Hum Genet 2001: 9: 773-779.
34. Neuhausen SL, Godwin AK, Gershoni-Baruch R et al. Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. Am J Hum Genet 1998: 62: 1381-1388.
35. Lahti-Domenici J, Rapakko K, Pääkkönen K et al. Exclusion of large deletions and other rearrangements in BRCA1 and BRCA2 in Finnish breast and ovarian cancer families. Cancer Genet Cytogenet 2001: 129: 120-123.
36. Laurila E, Syrjäkoski K, Holli K, Kallioniemi A, Karhu R. Search for large genomic alterations of the BRCA1 gene in a Finnish population. Cancer Genet Cytogenet 2005: 163: 57-61.
37. Karhu R, Laurila E, Kallioniemi A, Syrjäkoski K. Large genomic BRCA2 rearrangements and male breast cancer. Cancer Detect Prev 2006: 30: 530-534.
38. Healey CS, Dunning AM, Teare DM et al. A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability. Nat Genet 2000: 26: 362-364.
39. The Breast Cancer Association Consortium. Commonly studied single-nucleotide polymorphisms and breast cancer: Results from the breast cancer association consortium. J Natl Cancer Inst 2006: 98: 1382-1396.
40. Auranen A, Spurdle AB, Chen X et al. BRCA2 Arg372His polymorphism and epithelial ovarian cancer risk. Int J Cancer 2003: 103: 427-430.